TY - JOUR
T1 - Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase II
AU - Alquicer, Glenda
AU - Sedlák, David
AU - Byun, Youngjoo
AU - Pavlíček, Jiří
AU - Stathis, Marigo
AU - Rojas, Camilo
AU - Slusher, Barbara
AU - Pomper, Martin G.
AU - Bartůněk, Petr
AU - Bařinka, Cyril
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ministry of Education, Youth and Sports of the Czech Republic (ME10031, LC06077); IRG (project number 249220); EMBO (installation grant #1978); and the IBT (AV0Z50520701) provided institutional support. Funding was also provided by National Institutes of Health (NIH) CA151838, MH080580, CA161056 and CA134675.
PY - 2012/9
Y1 - 2012/9
N2 - Glutamate carboxypeptidase II (GCPII) is an important target for therapeutic and diagnostic interventions aimed at prostate cancer and neurologic disorders. Here we describe the development and optimization of a high-throughput screening (HTS) assay based on fluorescence polarization (FP) that facilitates the identification of novel scaffolds inhibiting GCPII. First, we designed and synthesized a fluorescence probe based on a urea-based inhibitory scaffold covalently linked to a Bodipy TMR fluorophore (TMRGlu). Next, we established and optimized conditions suitable for HTS and evaluated the assay robustness by testing the influence of a variety of physicochemical parameters (e.g., pH, temperature, time) and additives. Using known GCPII inhibitors, the FP assay was shown to be comparable to benchmark assays established in the field. Finally, we evaluated the FP assay by HTS of a 20 000-compound library. The novel assay presented here is robust, highly reproducible (Z′ = 0.82), inexpensive, and suitable for automation, thus providing an excellent platform for HTS of small-molecule libraries targeting GCPII.
AB - Glutamate carboxypeptidase II (GCPII) is an important target for therapeutic and diagnostic interventions aimed at prostate cancer and neurologic disorders. Here we describe the development and optimization of a high-throughput screening (HTS) assay based on fluorescence polarization (FP) that facilitates the identification of novel scaffolds inhibiting GCPII. First, we designed and synthesized a fluorescence probe based on a urea-based inhibitory scaffold covalently linked to a Bodipy TMR fluorophore (TMRGlu). Next, we established and optimized conditions suitable for HTS and evaluated the assay robustness by testing the influence of a variety of physicochemical parameters (e.g., pH, temperature, time) and additives. Using known GCPII inhibitors, the FP assay was shown to be comparable to benchmark assays established in the field. Finally, we evaluated the FP assay by HTS of a 20 000-compound library. The novel assay presented here is robust, highly reproducible (Z′ = 0.82), inexpensive, and suitable for automation, thus providing an excellent platform for HTS of small-molecule libraries targeting GCPII.
KW - fluorescence polarization
KW - glutamate carboxypeptidase II
KW - high-throughput screening
KW - metallopeptidase
KW - prostate-specific membrane antigen
UR - http://www.scopus.com/inward/record.url?scp=84864997955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864997955&partnerID=8YFLogxK
U2 - 10.1177/1087057112451924
DO - 10.1177/1087057112451924
M3 - Article
C2 - 22751730
AN - SCOPUS:84864997955
SN - 1087-0571
VL - 17
SP - 1030
EP - 1040
JO - Journal of Biomolecular Screening
JF - Journal of Biomolecular Screening
IS - 8
ER -